Medicare bill aims to block drugmakers from misclassifying drugs

A bipartisan bill introduced Tuesday by members of the Senate Finance Committee would prevent drugmakers from profiting by misclassifying drugs to Medicare as generics.

The bill is in response to a lawsuit against Mylan N.V. (NASDAQ:MYL) for misclassifying its EpiPen as a generic in order to shrink its required Medicaid rebate. The company settled the suit in 2016 with an agreement to pay the government $465 million (see "Mylan Inflammation News")...